Journals / Anadolu Psikiyatri Dergisi / 2004 / Cilt: 5 - Sayı: 4

The effect of atypical antipsychotics on MMSE in schizophrenic patients: A naturalistic and comparative study with typical antipsychotics

Atipik antipsikotik ilaçların şizofreni hastalarında kısa kognitif muayene (KKM) üzerine etkisi: Tipik antipsikotiklerle karşılaştırılmalı-doğal izlem çalışması

Pages
206–212
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Randomized, long term and larger sampled studies where more variables might be controlled are needed on this issue.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate the effect of atypical antipsychotic drugs on cognitive dysfunction in schizophrenia and to compare this effect with typical antipsychotics.
📊
Key Findings & Data:Twenty-five patients were on typical antipsychotic treatment and the rest 38 patients were on atypical.
💡
Conclusion & Impact:Randomized, long term and larger sampled studies where more variables might be controlled are needed on this issue.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Nörodavranışsal belirtiler · Şizofreni · Antipsikotik ajanlar

Abstract

Objective: To investigate the effect of atypical antipsychotic drugs on cognitive dysfunction in schizophrenia and to compare this effect with typical antipsychotics. Method: Sixty-three patients from Ege University Faculty of Medicine Department of Psychiatry who was treated as outpatient were enrolled to study. Twenty-five patients were on typical antipsychotic treatment and the rest 38 patients were on atypical. We applied Scale for Assessment of Positive and Negative Symptoms (SANS and SAPS), Hamilton Depression Rating Scale (HDRS) and MMSE at the beginning of treat-ment and at the end of second month to all patients. Results: Fifty-five patients of whom 24 were on typical and 31 on atypical antipsychotic treatment completed the study. The severity of cognitive dysfunction in atypical antipsychotic group significantly decreased at the end of second month. There was no significant difference between typical and atypical antipsychotic groups in decreasing the severity of cognitive dysfunction. The improvement of cognitive dysfunction in typical antipsychotic group is significantly correlated with both the improvement in negative and positive symptoms while the improvement of cognitive dysfunction in atypical antipsychotic group is only significantly correlated with the improvement in negative, symptoms. Discussion: We found that both typical and atypical antipsychotics significantly improve cognitive functions in schizophrenia. Randomized, long term and larger sampled studies where more variables might be controlled are needed on this issue.

Özet

Amaç: Atipik antipsikotik ilaçların şizofrenideki bilişsel bozukluklara etkisini araştırmak ve bu etkiyi tipik antipsikotik ilaçlarla karşılaştırmak. Yöntem: Ege Üniversitesi Tıp Fakültesi Psikiyatri Kliniği'nde ayaktan tedavi başlanan, 25 tipik antipsikotik ve 38 atipik antipsikotik kullanan toplam 63 hasta alındı. Hastalara tedavinin başlangıcında ve ikinci ayın sonunda Pozitif Belirtileri değerlendirme Ölçeği (SAPS), Negatif Belirtileri Değerlendirme Ölçeği (SANS), Hamilton Depresyon Derecelendirme Ölçeği (HDRS) ve Kısa Kognitif Muayene (KKM) Ölçeği uygulandı. Sonuç: Yirmi dört tipik antipsikotik ve 31 atipik antipsikotik kullanan toplam 55 hasta çalışmayı tamamladı. Atipik antipsikotik ilaç kullanan hasta grubunda ikinci ayın sonunda bilişsel bozukluğun şiddetinde anlamlı düzelme saptanmıştır. Ancak tipik antipsikotik kullanan hasta grubu ile atipik antipsikotik kullanan hasta grubu arasında bilişsel bozukluğun şiddetindeki düzelme açısından anlamlı fark saptanmamıştır. Tipik antipsikotik grubunda bilişsel işlevlerdeki düzelme hem negatif hem de pozitif belirtilerdeki düzelmeyle anlamlı olarak ilişkili bulunurken, atipik antipsikotik grubunda ise bilişsel işlevlerdeki düzelme sadece negatif belirtilerdeki düzelmeyle ilişkili bulunmuştur. Tartışma: Çalışmamızda atipik ve tipik antipsikotik ilaçların bilişsel işlevlerde anlamlı oranda düzelmeye neden olduğu bulunmuştur. Ancak bu konuda tüm değişkenlerin kontrol edildiği, izlem süresinin daha uzun olduğu ve hastaların randomize olarak seçildiği daha geniş örneklemli çalışmalara ihtiyaç vardır.

🔖

Cite This Article

KAYAHAN, B., VEZNEDAROĞLU, B., ÖZTÜRK, Ö., ERSOY, M. A. (2004). The effect of atypical antipsychotics on MMSE in schizophrenic patients: A naturalistic and comparative study with typical antipsychotics. Anadolu Psikiyatri Dergisi, Cilt: 5 - Sayı: 4, 206–212. https://ajindex.com/articles/356077

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lindström LH. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand 1994; 89 (suppl 380):74-76
  2. Weinberger DR, Gallhofer B. Cognitive function in schizophrenia. Int Clin Psychopharmacology 1997; 12 (suppl 4):S29-S36
  3. Borison RL. The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatr Scand 1996; 94:5-11
  4. Mortimer AM. Cognitive functions in schizophrenia-Do neuroleptics make difference? Pharmacol Biochem Behav 1997; 56:789-795
  5. Ganguli R, Brar JS, Vemulapalli H, Jafar H, Ahuja R, Sharma S ve ark. Mini-Mental State Examination (MMSE) performance of partially remitted community-dwelling patients with schizophrenia. Schizophr Res 1998; 33:45-52
  6. Gallhofer B, Lis S, Meyer-Lindenberg A, Krieger S. Cognitive dysfunction in schizophrenia: a new set of tools for the assessment of cognition and drug effects. Acta Psychiatr Scand 1999; 99 (Suppl 395): 118-128
  7. Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY. Improvement in cognitive function and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 1993; 34:702-712
  8. Goldberg TE, Torrey EF, Gold JM, Ragland JD, Bigelow LB, Weinberger DR. The effect of clozapine on cogniton and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 1993; 162:43-48
  9. Buchanan RW, Holstein C, Breier A. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biological Psychiatry 1994; 36:717-725
  10. Stip E, Lussier I. The effect of risperidone on cognition in patients with schizophrenia. Canadian Journal Psychiatry 1996; 41(Suppl 2):35-40
  11. Rossi A, Mancini F, Stratta P, Mattei P, Gismondi R, Pozzi F ve ark. Risperidone, negative symptoms, and cognitive deficit in schizophrenia: An open study. Acta Psychiatr Scand 1997; 95:40-43
  12. Lee MA, Jayathilake K, Meltzer HY. A comparison of the effect of clozapine with typical neuroleptics on cognitive function on neuroleptic responsive schizophrenia. Schizophrenia Research 1999; 37:1-11
  13. Meltzer HY, Mc Gurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999; 25:233-255
  14. Pallanti S, Quercioli L, Pazzagli A. Effects of clozapine on awareness of illness and cognition in schizophrenia. Psychiatry Re